

ASX / Media Release

11 February 2011

RHT: Resonance Health Signs Agreement with Pfizer

The Board of Resonance Health is pleased to announce it has signed an Agreement with Pfizer to evaluate the company's MRI-based product for assessing liver fibrosis. The Agreement follows the Company's announcement last year to seek partners for the next stage of development and the Company is delighted that Pfizer has recognised the potential value of the Company's liver fibrosis test.

Liver fibrosis is a major international health problem caused primarily by hepatitis C infection, excessive alcohol consumption, and fatty liver disease. The currently recognised gold standard for assessing liver fibrosis involves a liver biopsy, a technique presenting risk to the patient and inaccuracies due to sampling error. By removing the need for a liver biopsy, an imaging based liver fibrosis test enables repeat measurements to be made safely and the potential for the earlier detection of liver fibrosis resulting in a better outcome for patients.

The Company's development activities into an MRI-based diagnostic product for liver fibrosis have provided promising results. The Agreement with Pfizer involves a clinical study in collaboration with Professor Peter Angus, Medical Director Liver Transplant Unit, at the Austin Hospital in Melbourne. This study affords the opportunity to assess product improvements aimed at achieving a higher level of accuracy in distinguishing between the various stages of liver fibrosis and to compare the results with a liver biopsy fibrosis grade.

The results of this study are expected in the first quarter of 2012 at which time an assessment will be made to determine whether further research is needed or whether the Company can move directly to seeking regulatory approval for the test.

This announcement represents a significant opportunity for Resonance Health to collaborate with a large pharmaceutical company and further develop its product portfolio in imaging diagnostics.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Colin McDonald
Company Secretary
T: +61 8 9286 5300
E: colinm@ferriscan.com

About Resonance Health Ltd

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company developing innovative imaging technology for the assessment of human disease. The Company's expertise is in providing quantitative measurements using MRI technology replacing the need for invasive procedures such as a biopsy. Its lead product on market is FerriScan[®], for the measurement of iron overload. Pipeline products include imaging products for the measurement of liver fat and liver fibrosis. A recently agreed exclusive worldwide license for a product providing an imaging based measurement of amyloidosis and fibrosis provides an expanding portfolio of products for the Company.